Business
Goldman Small Cap Research Publishes New Research Report on Regen BioPharma, Inc.
Goldman Small Cap Research Publishes New Research Report on Regen BioPharma, Inc..
About this update from Regen Biopharma, Inc.
[{"type":"text","content":"\r\n\r\n \r\n \r\n Goldman Small Cap Research Publishes New Research Report on Regen BioPharma, Inc. \r\n \r\n \r\n\r\n\r\nGoldman Small Cap Research Publishes New Research Report on Regen BioPharma, Inc. \r\n\r\n\r\n\r\n\r\n\r\nBALTIMORE, MD / ACCESS Newswire / November 5, 2025 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new research report on Regen BioPharma, Inc. (OTCID:RGBP, RGBPP), a biopharma developer that seeks to rapidly advance novel technologies through pre-clinical and Phase I/ II clinical trials. The Goldman report carries a price target. To view the new research report, along with disclosures and disclaimers, or to download the report in its entirety, please visit: https://goldmansmallcapresearch.com/opportunity-research/imminent-phase-i-clinical-trial-launch-to-drive-major-valuation-upside/\r\n Regen BioPharma, Inc. is focused on developing innovative treatments using autologous cell therapies, RNA and DNA-based immunotherapy and small molecules in the immune-oncology segment. The Company has an FDA-cleared IND for its Phase I clinical trial candidate HemaXellerate, an innovative stem cell-derived therapy.\r\n In the Opportunity Research report, analyst Rob Goldman reviews this undervalued and underfollowed innovator including upcoming milestones and events, a peer group analysis, deep pipeline, and valuation drivers.\r\n Set to Enter Clinical Stage\r\n Goldman commented, \"Regen is on the cusp of making a major leap from the preclinical biopharma stage to a clinical stage biopharma, which typically serves as a foundational valuation driver. The Company's lead candidate, HemaXellerate, is an innovative stem cell-derived therapy and the Company plans to launch a Phase I clinical trial by year-end or in early 1Q26. HemaXellerate's primary indication is to treat chemotherapy patients who have developed a potentially terminal side effect, severe aplastic anemia. The only approved therapy is a costly stem cell transplant, which needs a matched donor and can lead to graft-versus-host disease. Still, the Regen therapy represents $1 billion in market size.\"\r\n Multiple, Enviable Development Pathways\r\n \"Regen has applied for an Orphan Drug Designation for this product, which would be a major coup for the Company,...